Trademark applications and grants for Aclaris Therapeutics Inc. Aclaris Therapeutics Inc has 33 trademark applications. The latest application filed is for "ACLARIS"
Patent Application | Date |
---|---|
DEUTERATED MK2 PATHWAY INHIBITORS AND METHODS OF USING THE SAME 20220288070 - 17/630414 ANDERSON; David Randolph ;   et al. | 2022-09-15 |
SUBSTITUTED SULFONAMIDE PYRROLOPYRIDINES AS JAK INHIBITORS 20220235043 - 17/609701 ANDERSON; David Randolph ;   et al. | 2022-07-28 |
METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS 20220235025 - 17/533931 DECRESCENZO; Gary A. ;   et al. | 2022-07-28 |
ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS 20210338669 - 17/214532 SMITH; Walter ;   et al. | 2021-11-04 |
SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME 20210284637 - 17/203482 ANDERSON; David Randolph ;   et al. | 2021-09-16 |
SEC | 0001557746 | Aclaris Therapeutics, Inc. of DELAWARE |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.